Deutsche Bank Ag\ Nektar Therapeutics Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Nektar Therapeutics stock. As of the latest transaction made, Deutsche Bank Ag\ holds 88,549 shares of NKTR stock, worth $94,747. This represents 0.0% of its overall portfolio holdings.

Number of Shares

88,549

Holding current value

$94,747

% of portfolio

0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$1.11 - $1.48 $98,289 - $131,052	88,549 New	88,549 $115,000
Q1 2023 May 15, 2023	BUY	$0.64 - $3.15 $20,764 - $102,198	32,444 Added 33.36%	129,708 $90,000
Q4 2022 Feb 13, 2023	BUY	$2.03 - $4.28 $31,154 - $65,685	15,347 Added 18.73%	97,264 $219,000
Q3 2022 Nov 14, 2022	SELL	$3.04 - $5.14 $273,976 - $463,237	-90,124 Reduced 52.39%	81,917 $262,000
Q2 2022 Aug 11, 2022	BUY	$3.17 - $6.17 $357,588 - $696,000	112,804 Added 190.43%	172,041 $653,000
Q1 2022 May 13, 2022	SELL	$4.16 - $13.72 $761 - $2,510	-183 Reduced 0.31%	59,237 $320,000
Q4 2021 Feb 11, 2022	SELL	$10.83 - $18.41 $43,081 - $73,234	-3,978 Reduced 6.27%	59,420 $803,000
Q3 2021 Nov 04, 2021	BUY	$13.07 - $18.84 $614,002 - $885,065	46,978 Added 286.1%	63,398 $1.14 Million
Q2 2021 Aug 11, 2021	SELL	$16.52 - $20.4 $180,398 - $222,767	-10,920 Reduced 39.94%	16,420 $281,000
Q1 2021 May 13, 2021	BUY	$16.56 - $25.46 $212,613 - $326,880	12,839 Added 88.54%	27,340 $546,000
Q4 2020 Feb 16, 2021	SELL	$15.77 - $19.03 $967,915 - $1.17 Million	-61,377 Reduced 80.89%	14,501 $246,000
Q3 2020 Nov 12, 2020	BUY	$16.59 - $24.79 $714,332 - $1.07 Million	43,058 Added 131.19%	75,878 $1.26 Million
Q2 2020 Aug 13, 2020	SELL	$16.86 - $23.44 $5.58 Million - $7.76 Million	-331,158 Reduced 90.98%	32,820 $760,000
Q1 2020 May 14, 2020	SELL	$14.47 - $27.96 $4.03 Million - $7.78 Million	-278,398 Reduced 43.34%	363,978 $6.5 Million
Q4 2019 Feb 14, 2020	SELL	$15.87 - $23.12 $6.41 Million - $9.34 Million	-403,974 Reduced 38.61%	642,376 $13.9 Million
Q3 2019 Nov 14, 2019	SELL	$16.91 - $36.27 $3.64 Million - $7.81 Million	-215,426 Reduced 17.07%	1,046,350 $19.1 Million
Q2 2019 Aug 14, 2019	BUY	$31.0 - $36.3 $22.5 Million - $26.4 Million	726,517 Added 135.73%	1,261,776 $44.9 Million
Q1 2019 May 15, 2019	SELL	$31.58 - $46.35 $13 Million - $19.1 Million	-411,745 Reduced 43.48%	535,259 $18 Million
Q4 2018 Feb 14, 2019	BUY	$30.43 - $56.65 $10.9 Million - $20.2 Million	356,674 Added 60.42%	947,004 $31.1 Million
Q3 2018 Dec 21, 2021	BUY	$46.46 - $68.49 $8.43 Million - $12.4 Million	181,496 Added 44.39%	590,330 $36 Million
Q3 2018 Nov 14, 2018	SELL	$46.46 - $68.49 $6.05 Million - $8.92 Million	-130,177 Reduced 24.15%	408,834 $24.9 Million
Q2 2018 Apr 21, 2020	BUY	$46.25 - $104.45 $5.3 Million - $12 Million	114,617 Added 27.01%	539,011 $26.3 Million
Q2 2018 Aug 14, 2018	SELL	$46.25 - $104.45 $6.97 Million - $15.7 Million	-150,614 Reduced 26.19%	424,394 $20.7 Million
Q1 2018 Oct 18, 2019	BUY	$57.4 - $108.44 $6.34 Million - $12 Million	110,528 Added 23.8%	575,008 $61.1 Million
Q1 2018 May 15, 2018	BUY	$57.4 - $108.44 $5.42 Million - $10.2 Million	94,478 Added 25.53%	464,480 $49.4 Million
Q4 2017 Feb 14, 2018	SELL	$23.02 - $60.5 $20.6 Million - $54.2 Million	-895,293 Reduced 70.76%	370,002 $22.1 Million
Q3 2017 Nov 14, 2017	BUY	$17.79 - $24.0 $22.5 Million - $30.4 Million	1,265,295	1,265,295 $30.4 Million

Others Institutions Holding NKTR

# of Institutions

147

Shares Held

139M

Call Options Held

32.6K

Put Options Held

14.1K

Deep Track Capital, LP Greenwich, CT

15.9M
Shares

$17 Million
0.76% of portfolio
Black Rock Inc. New York, NY

15.2M
Shares

$16.2 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

13.1M
Shares

$14 Million
0.0% of portfolio
Eventide Asset Management, LLC Boston, MA

9.4M
Shares

$10.1 Million
0.22% of portfolio
Samlyn Capital, LLC New York, NY

9.2M
Shares

$9.84 Million
0.19% of portfolio

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $201M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account